基于纵向血液生物标志物的脑损伤评估患者接受深部脑刺激和磁共振引导聚焦超声。

IF 7.6 1区医学 Q1 CLINICAL NEUROLOGY

Movement Disorders Pub Date : 2025-09-30 DOI:10.1002/mds.70071

Justina Dargvainiene,Ann-Kristin Helmers,Juliana Naumann,Carl Alexander Gless,Bettina Möller,Julius Welzel,Frank Leypoldt,Johannes Hensler,Ina Tesseur,Klaus-Peter Wandinger,Günther Deuschl,Daniela Berg,Steffen Paschen

{"title":"基于纵向血液生物标志物的脑损伤评估患者接受深部脑刺激和磁共振引导聚焦超声。","authors":"Justina Dargvainiene,Ann-Kristin Helmers,Juliana Naumann,Carl Alexander Gless,Bettina Möller,Julius Welzel,Frank Leypoldt,Johannes Hensler,Ina Tesseur,Klaus-Peter Wandinger,Günther Deuschl,Daniela Berg,Steffen Paschen","doi":"10.1002/mds.70071","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nDeep brain stimulation (DBS) and magnetic resonance-guided focused ultrasound (MRgFUS) are associated with neuroaxonal damage and astroglial activation; yet their extent and timing remain unclear despite clinical relevance for monitoring and outcome assessment.\r\n\r\nOBJECTIVE\r\nThis study assessed neuroaxonal damage and astroglial activation after DBS (n = 21) and MRgFUS (n = 19) reflected by serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP).\r\n\r\nMETHODS\r\nSamples were collected at baseline, 24 h, 7 days, and 3/6/9 months posttreatment. Biomarker levels were measured using a single-molecule array (Simoa).\r\n\r\nRESULTS\r\nsNfL peaked at day 7 and sGFAP at 24 h post-intervention in both groups. sNfL normalized at 6 months in DBS and 3 months in MRgFUS. sGFAP normalized within 7 days in both groups. Biomarker elevations were higher in DBS patients.\r\n\r\nCONCLUSIONS\r\nDBS and MRgFUS cause transient neuroaxonal injury and astroglial activation, with greater extent in DBS. Biomarker monitoring suggests final clinical evaluation should be performed 6 months after treatment at the earliest. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.","PeriodicalId":213,"journal":{"name":"Movement Disorders","volume":"19 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Longitudinal Blood-Biomarker-Based Assessment of Brain Injury in Patients Undergoing Deep Brain Stimulation and Magnetic Resonance-Guided Focused Ultrasound.\",\"authors\":\"Justina Dargvainiene,Ann-Kristin Helmers,Juliana Naumann,Carl Alexander Gless,Bettina Möller,Julius Welzel,Frank Leypoldt,Johannes Hensler,Ina Tesseur,Klaus-Peter Wandinger,Günther Deuschl,Daniela Berg,Steffen Paschen\",\"doi\":\"10.1002/mds.70071\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\r\\nDeep brain stimulation (DBS) and magnetic resonance-guided focused ultrasound (MRgFUS) are associated with neuroaxonal damage and astroglial activation; yet their extent and timing remain unclear despite clinical relevance for monitoring and outcome assessment.\\r\\n\\r\\nOBJECTIVE\\r\\nThis study assessed neuroaxonal damage and astroglial activation after DBS (n = 21) and MRgFUS (n = 19) reflected by serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP).\\r\\n\\r\\nMETHODS\\r\\nSamples were collected at baseline, 24 h, 7 days, and 3/6/9 months posttreatment. Biomarker levels were measured using a single-molecule array (Simoa).\\r\\n\\r\\nRESULTS\\r\\nsNfL peaked at day 7 and sGFAP at 24 h post-intervention in both groups. sNfL normalized at 6 months in DBS and 3 months in MRgFUS. sGFAP normalized within 7 days in both groups. Biomarker elevations were higher in DBS patients.\\r\\n\\r\\nCONCLUSIONS\\r\\nDBS and MRgFUS cause transient neuroaxonal injury and astroglial activation, with greater extent in DBS. Biomarker monitoring suggests final clinical evaluation should be performed 6 months after treatment at the earliest. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.\",\"PeriodicalId\":213,\"journal\":{\"name\":\"Movement Disorders\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Movement Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/mds.70071\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Movement Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/mds.70071","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

脑深部刺激（DBS）和磁共振引导聚焦超声（MRgFUS）与神经轴突损伤和星形胶质细胞激活有关；尽管监测和结果评估具有临床意义，但其范围和时间仍不清楚。目的通过血清神经丝轻链（sNfL）和血清胶质纤维酸性蛋白（sGFAP）来评估DBS （n = 21）和MRgFUS （n = 19）后的神经轴突损伤和星形胶质细胞激活情况。方法分别于治疗后基线、24 h、7 d和3/6/9个月采集样本。使用单分子阵列（Simoa）测量生物标志物水平。结果两组患者snfl在干预后第7天达到峰值，sGFAP在干预后24 h达到峰值。在DBS和MRgFUS中，sNfL在6个月和3个月时恢复正常。两组sGFAP均在7天内恢复正常。DBS患者的生物标志物升高更高。结论DBS和MRgFUS可引起短暂性神经轴突损伤和星形胶质细胞激活，且DBS损伤程度更大。生物标志物监测表明，最终临床评估应在治疗后6个月进行。©2025作者。Wiley期刊有限责任公司代表国际帕金森和运动障碍学会出版的《运动障碍》。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Longitudinal Blood-Biomarker-Based Assessment of Brain Injury in Patients Undergoing Deep Brain Stimulation and Magnetic Resonance-Guided Focused Ultrasound.

BACKGROUND Deep brain stimulation (DBS) and magnetic resonance-guided focused ultrasound (MRgFUS) are associated with neuroaxonal damage and astroglial activation; yet their extent and timing remain unclear despite clinical relevance for monitoring and outcome assessment. OBJECTIVE This study assessed neuroaxonal damage and astroglial activation after DBS (n = 21) and MRgFUS (n = 19) reflected by serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP). METHODS Samples were collected at baseline, 24 h, 7 days, and 3/6/9 months posttreatment. Biomarker levels were measured using a single-molecule array (Simoa). RESULTS sNfL peaked at day 7 and sGFAP at 24 h post-intervention in both groups. sNfL normalized at 6 months in DBS and 3 months in MRgFUS. sGFAP normalized within 7 days in both groups. Biomarker elevations were higher in DBS patients. CONCLUSIONS DBS and MRgFUS cause transient neuroaxonal injury and astroglial activation, with greater extent in DBS. Biomarker monitoring suggests final clinical evaluation should be performed 6 months after treatment at the earliest. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Movement Disorders 医学-临床神经学

CiteScore

13.30

自引率

8.10%

发文量

371

审稿时长

12 months

期刊介绍： Movement Disorders publishes a variety of content types including Reviews, Viewpoints, Full Length Articles, Historical Reports, Brief Reports, and Letters. The journal considers original manuscripts on topics related to the diagnosis, therapeutics, pharmacology, biochemistry, physiology, etiology, genetics, and epidemiology of movement disorders. Appropriate topics include Parkinsonism, Chorea, Tremors, Dystonia, Myoclonus, Tics, Tardive Dyskinesia, Spasticity, and Ataxia.